MX2024007089A - Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino. - Google Patents

Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino.

Info

Publication number
MX2024007089A
MX2024007089A MX2024007089A MX2024007089A MX2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A MX 2024007089 A MX2024007089 A MX 2024007089A
Authority
MX
Mexico
Prior art keywords
receptor alpha
canine
canine interleukin
caninized antibodies
antibodies
Prior art date
Application number
MX2024007089A
Other languages
English (en)
Spanish (es)
Inventor
Mohamad Morsey
Yuanzheng Zhang
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2024007089A publication Critical patent/MX2024007089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024007089A 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino. MX2024007089A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163290259P 2021-12-16 2021-12-16
US202163290256P 2021-12-16 2021-12-16
US202263341443P 2022-05-13 2022-05-13
PCT/EP2022/086084 WO2023111148A1 (en) 2021-12-16 2022-12-15 Caninized antibodies to canine interleukin-31 receptor alpha 1

Publications (1)

Publication Number Publication Date
MX2024007089A true MX2024007089A (es) 2024-08-22

Family

ID=84923386

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2024007089A MX2024007089A (es) 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino.
MX2024007090A MX2024007090A (es) 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024007090A MX2024007090A (es) 2021-12-16 2022-12-15 Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.

Country Status (7)

Country Link
US (2) US20250340653A1 (cg-RX-API-DMAC7.html)
EP (2) EP4448572A1 (cg-RX-API-DMAC7.html)
JP (2) JP2024546763A (cg-RX-API-DMAC7.html)
AU (2) AU2022409610A1 (cg-RX-API-DMAC7.html)
CA (2) CA3239826A1 (cg-RX-API-DMAC7.html)
MX (2) MX2024007089A (cg-RX-API-DMAC7.html)
WO (2) WO2023111128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021335500A1 (en) 2020-09-04 2023-05-04 Elanco Us Inc. Palatable formulations
US20250257142A1 (en) * 2024-02-13 2025-08-14 Invetx, Inc. Anti-il-31ra antibodies and uses thereof
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
WO2010031184A1 (en) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Azaindole derivatives as crth2 receptor antagonists
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
WO2021123092A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies for treating atopic dermatitis

Also Published As

Publication number Publication date
MX2024007090A (es) 2024-08-22
AU2022409603A1 (en) 2024-06-27
WO2023111148A1 (en) 2023-06-22
US20250340653A1 (en) 2025-11-06
WO2023111128A1 (en) 2023-06-22
CA3239307A1 (en) 2023-06-22
US20250340654A1 (en) 2025-11-06
AU2022409610A1 (en) 2024-05-30
JP2024546763A (ja) 2024-12-26
CA3239826A1 (en) 2023-06-22
EP4448571A1 (en) 2024-10-23
EP4448572A1 (en) 2024-10-23
JP2024546759A (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
MX2024007090A (es) Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.
MX2023004439A (es) Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina.
MX2023001727A (es) Anticuerpos anti-c5 y usos de los mismos.
MX2022007672A (es) Anticuerpos del receptor alfa de interleucina-4 canina.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
EP3954710A3 (en) Antibodies to canine interleukin-4 receptor alpha
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
WO2020086406A3 (en) Anti-npr1 antibodies and uses thereof
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
EP4541807A3 (en) Caninized human antibodies to human and canine il-4r alpha
ZA201807816B (en) Anti-il-22r antibodies
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
SG196839A1 (en) Antibodies against fcrn and use thereof
ZA202401100B (en) Human interleukin-4 receptor alpha antibodies
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
PH12019502617A1 (en) Antibody-cytokine engrafted proteins and methods of use for immune related disorders
MA43088A1 (fr) Anticorps anti-il-17c
MX2022016494A (es) Anticuerpos anti-il13ra2.
PH12020550340A1 (en) Anti-pacap antibody
WO2023172990A3 (en) Epo receptor agonists and antagonists
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo